Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Strong growth
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Modest
About
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial...
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Strong growth
Very low or no dividends
Very poor margins and returns
$ 4.34
About
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial...